期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 97, 期 5, 页码 447-450出版社
WILEY
DOI: 10.1002/cpt.91
关键词
-
资金
- NCI NIH HHS [R21 CA170063, U10 CA180870, U10 CA180833, U24 CA196171] Funding Source: Medline
The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据